E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Uncertainty of the time of first significance in random effects cumulative meta-analysis.
TL;DR: These simulated meta-analyses demonstrate the main point, which is that the time of first significance, however parameterized, is itself a random variable with error variance.
Journal ArticleDOI
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Natalia S. Rost,Robert P. Giugliano,Christian T. Ruff,Sabina A. Murphy,Andrea E. Crompton,Andrew D. Norden,Scott Silverman,Aneesh B. Singhal,Jose C. Nicolau,Bhupathi SomaRaju,Michele Mercuri,Elliott M. Antman,Eugene Braunwald +12 more
TL;DR: HDER is at least as effective and is safer than warfarin, regardless of the presence or the absence of previous IS or TIA, and annualized intracranial hemorrhage rates were lower with HDER than with warfar in this prespecified subgroup analysis.
Journal ArticleDOI
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
Marc Cohen,Kenneth W. Mahaffey,Karen S. Pieper,Charles V. Pollack,Elliott M. Antman,James W. Hoekstra,Shaun G. Goodman,Anatoly Langer,Jacques Col,Harvey D. White,Robert M. Califf,James J. Ferguson +11 more
TL;DR: After adjustment for differences in baseline characteristics between subgroups, consistent therapy with enoxaparin might be superior to UFH in reducing death or nonfatal myocardial infarction, with a modest excess in bleeding.
Journal ArticleDOI
American College of Cardiology/American Heart Association Clinical Practice Guidelines: Part II Evolutionary Changes in a Continuous Quality Improvement Project
TL;DR: In this article, a 50-year-old male presented to his office for evaluation of a recent episode of atrial fibrillation, where he was working in a woodworking shop on a large cabinet and fell on his right great toe.
Journal ArticleDOI
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Jan Steffel,Robert P. Giugliano,Eugene Braunwald,Sabina A. Murphy,Dan Atar,Hein Heidbuchel,Alan John Camm,Elliott M. Antman,Christian T. Ruff +8 more
TL;DR: Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amioarone, while preserving a favourable bleeding profile.